Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Ana M AranceLuis de la Cruz MerinoTeresa M PetrellaRahima JamalLars NyAna CarneiroAlfonso BerrocalIvan Marquez-RodasAnna SpreaficoVictoria AtkinsonFernanda Costa SvedmanAndrew MantMuhammad A KhattakCatalin MihalcioiuSekwon JangC Lance CoweyAlan D SmithNatalyn HawkKe ChenScott J DiedeClemens KreplerGeorgina V LongPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Lenvatinib plus pembrolizumab provides clinically meaningful, durable responses in patients with advanced melanoma with confirmed PD on prior PD-1/L1 inhibitor-based therapy, including those with PD on anti-PD-1 plus anti-CTLA-4 therapy. The safety profile was as expected. These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need.